BioDelivery's opioid treatment wins FDA approval

(Reuters) - BioDelivery Sciences International Inc said the U.S. Food and Drug Administration had approved its opioid treatment for chronic pain, sending the drugmaker's shares up 23 percent in premarket trading on Monday.